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Abstract
Background: An in-frame deletion leading to the loss of a single glutamic acid residue in the protein torsinA (DE-torsinA) results in an inherited movement
disorder, DYT1 dystonia. This autosomal dominant disease affects the function of the brain without causing neurodegeneration, by a mechanism that remains
unknown.
Methods: We evaluated the literature regarding the subcellular localization of torsinA.
Results: Efforts to elucidate the pathophysiological basis of DYT1 dystonia have relied partly on examining the subcellular distribution of the wild-type and
mutated proteins. A typical approach is to introduce the human torsinA gene (TOR1A) into host cells and overexpress the protein therein. In both neurons and non-
neuronal cells, exogenous wild-type torsinA introduced in this manner has been found to localize mainly to the endoplasmic reticulum, whereas exogenous DE-
torsinA is predominantly in the nuclear envelope or cytoplasmic inclusions. Although these outcomes are relatively consistent, findings for the localization of
endogenous torsinA have been variable, leaving its physiological distribution a matter of debate.
Discussion: As patients’ cells do not overexpress torsinA proteins, it is important to understand why the reported distributions of the endogenous proteins are
inconsistent. We propose that careful optimization of experimental methods will be critical in addressing the causes of the differences among the distributions of
endogenous (non-overexpressed) vs. exogenously introduced (overexpressed) proteins.
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Introduction
DYT1 dystonia is defined as ‘‘early-onset generalized isolated
dystonia’’.1 It is characterized by involuntary muscle contractions and
abnormal postures, and caused by a mutation in the TOR1A gene
(c.904_906delGAG/c.907_909delGAG; p.Glu302del/p.Glu303del)
that results in deletion of a glutamic acid residue from the torsinA
protein (DE-torsinA).2–6 Patients with this autosomal dominant
disorder are heterozygous for the mutation (TOR1A+/DE). TorsinA
belongs to the AAA+ family (ATPases associated with various cellular
activities).7 Its ATPase activity is regulated by proteins in the
endoplasmic reticulum (ER) and nuclear envelope,8 and is thought
to contribute to diverse cellular processes, including the unfolding of
proteins during their degradation, the disassembly of protein
aggregates, and the disassembly of protein complexes.7 Although the
biochemical properties of torsinA have been identified, how it
contributes to neuronal function in the brain remains elusive.
Because the first dystonia gene locus to be identified was for DYT1
dystonia, it serves as a paradigm for the pathogenesis and
pathophysiology of this debilitating neurological disorder.
Knowledge of the subcellular distribution of torsinA is expected to
provide insight into its function and the pathogenesis that occurs when
it is mutated. According to a prevailing model for the localization and
function of torsinA proteins, the wild-type form is present throughout
the ER whereas the DE form is present in the nuclear envelope and
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causes abnormalities in its ultrastructure (reviewed, e.g., in Granata
et al.9). This proposed spatial redistribution of torsinA is thought to
play a critical role in dystonia pathogenesis, because neuronal
dysfunction can be caused by either a lack of wild-type torsinA or
an accumulation of DE-torsinA in certain subcellular compartments.
However, this model is based largely on studies in which expression of
exogenous torsinA in host cells was forced (overexpression), and levels
of the protein were much higher than in the endogenous state. As the
total content of torsinA (wild-type plus DE-torsinA) in patient
fibroblasts is similar to, or even slightly reduced from, that in normal
subjects,10–12 it is possible that the results from overexpression studies
reflect a cellular state that is distinct from DYT1 dystonia.
The objective of this article is to compare imaging-based results
obtained from exogenous overexpression in host cells with those for
endogenous expression in a natural context, and to identify issues that
will need to be resolved in order to settle the question of endogenous
torsinA localization.
Search strategy and selection criteria
PubMED searches of articles were carried out using the terms
‘‘DYT1 dystonia,’’ ‘‘torsinA,’’ ‘‘TOR1A,’’ ‘‘distribution,’’ or ‘‘localiza-
tion.’’ No time limits were placed. The reference lists of the primary
articles were also searched. Only mammalian studies reported in full-
text articles written in English were analyzed.
Consistent localization results with overexpression systems
In overexpression systems, the human torsinA genes are exogen-
ously introduced into model animals or cells. The distribution of
overexpressed torsinA is typically evaluated by one of three methods:
1) torsinA is tagged with a fluorescent protein (fluorescence tag, e.g.,
green fluorescent protein [GFP], cyan fluorescent protein [CFP]) and
its fluorescence is detected; 2) torsinA is tagged with a non-fluorescent
peptide (epitope-tag, e.g., myc-tag, V5-tag, polyhistidine-tag) and is
detected by immunocytochemistry using an anti-tag antibody; or 3)
untagged torsinA is overexpressed and detected by immunocytochem-
istry using an anti-torsinA antibody. Western blotting was used to
measure the fold increase in the level of protein overexpression. The
value has been reported as ,1.3 to 1.5,13 ,1.3 to 2.3,14 ,2 to 6,15 in
transgenic mice, and as high as ,2 to ,20,16 or ,10 to 50 in some
cultured cells.17,18 In studies where the Western blotting results were
not quantified, the signals from endogenous protein were very weak or
not detectable, in comparison to the overexpressed protein in cultured
cells.19–21
Overexpression studies have provided relatively consistent results
(Table 1). In Table 1, the reported data are entered according to the
host cell types, and these are broadly classified into cultured non-
neuronal cells, cultured tumor cells of neuronal origin, cultured
neurons, and neurons in situ. All of the host cells had a wild-type
background. For the sake of highlighting the potential variations
among individual reports, the entries for a particular cell type are
grouped together only where exactly the same result regarding either
the subcellular distribution of torsinA or its colocalization with
organellar markers was reported by the same group of researchers.
In the case of wild-type torsinA, overexpressed protein was localized
mainly in the ER, resulting in diffuse cytoplasmic—or where the
resolution was high enough tubular or reticular—staining. At the level
of light microscopy, the ER domain was almost equivalent to the
cytoplasmic domain. A minor component of the signal emanated from
the nuclear envelope (which is contiguous with the ER), in a
perinuclear, ring-like pattern around the nucleoplasm. In the case of
DE-torsinA, by contrast, the overexpressed protein was present mainly
at the nuclear envelope and/or in cytoplasmic inclusion bodies. A
minor component was present in the ER. Notably, the distributions of
wild-type and DE forms of torsinA were not specific to the host cell
types used, to whether the cells examined were cultured or in brain
slices (in situ), or to the brain regions analyzed. Rather the distributions
corresponded to whether it was wild-type or DE-torsinA that was
overexpressed. Thus the general conclusion from these findings was
that the signature feature of DYT1 dystonia is the mislocalization of
DE-torsinA.
Advantages of overexpression systems
Overexpression systems are widely used, in part because they make
it possible to introduce recombinant forms of torsinA with modifica-
tions. Other advantages of overexpression systems include the
following: a fluorescence tag can be used to reveal torsinA localization,
and the intensity of the tag is much stronger than background noise
(autofluorescence); an epitope-tag can be used to reveal torsinA
localization, and it can be detected with antibodies with high specificity
for antigens not normally present in tissue; and, when an anti-torsinA
antibody is used in this context, the signal of the overexpressed protein
will be well above the background noise or endogenous signal, even
though its affinity for torsinA may be lower than those of anti-tag
antibodies for their respective tags. These overexpression systems have
advantages in addition to their usefulness in analyzing the subcellular
localization of torsinA. For example, they have been used to identify
interacting partners of torsinA (reviewed, e.g., in Warner et al. 22), to
purify the torsinA protein,8,19 to measure the rate of turnover of
torsinA protein,23 to evaluate the effects of torsinA in specific types of
neurons,24 and to establish what effects torsinA has on cell biological
processes such as the ER- and oxidative-stress responses, and the
chaperoning of proteins (reviewed, e.g., in Bragg et al.6).
Disadvantages of overexpression systems
Overexpression systems are associated with several general issues,
including potentially violating balanced gene dosage, and affecting the
folding of proteins, the assembly of protein complexes, and the
regulation of downstream signaling.25 In addition, overexpression
systems have at least two disadvantages specific to the study of torsinA.
One is that the distribution of torsinA is known to change depending
on the expression level (Table 2). When DE-torsinA expression is low,
it is present in the nuclear envelope (e.g. two- to 10-fold increase from
the endogenous level), whereas when its expression is high, it is
preferentially localized to cytoplasmic inclusions (e.g. ,20-fold
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Table 1. Genotype-dependent Subcellular Distributions of Overexpressed Human TorsinA Proteins in Mammalian Systems







(–) Armata et al.76
Human fibroblasts Diffuse cytoplasmic (colocalized
with PDI); no TEM abnormality
of nuclear envelope
Inclusions; abnormal TEM of
nuclear envelope
Hettich et al.77
Human glioma Gli36 cells Diffuse cytoplasmic (colocalized
with PDI); perinuclear staining
Inclusions; perinuclear Bragg et al.78





inclusions (not colocalized with






inclusions (,5% of cells)









Vander Heyden et al.80
Human osteosarcoma
U2OS cells
Diffuse cytoplasmic (–) Naismith et al.81
Human osteosarcoma
U2OS cells
Diffuse cytoplasmic (excluded from
ER exit sites)
























Inclusions (in.95% of cells) O’Farrell et al.21,84
Human embryonic kidney
epithelial HEK293 cells






Diffuse cytoplasmic Inclusions; these form whether or





Diffuse cytoplasmic (–) Armata et al.76
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Table 1. Continued
Cell Type/Name WT-torsinA DE-torsinA References
Human embryonic kidney
epithelial HEK293 cells
(–) (no light-microscopic data; normal
TEM of nuclear envelope)
(–) (no light-microscopic data;











Diffuse cytoplasmic (colocalized with
PDI)




Diffuse cytoplasmic (colocalized with
GRP78/BiP); perinuclear; (N-terminus
was modified to increase expression
level in Kustedjo et al.87)
Inclusions (not colocalized with
GRP78/BiP); not perinuclear; (N-
terminus was modified to increase
























Diffuse cytoplasmic (colocalized with
PDI)




Diffuse cytoplasmic (only partly
colocalized with calreticulin, the
soluble lumenal protein present
throughout the ER, indicating that
torsinA prefers ER flat sheet to ER
tubules)








Diffuse cytoplasmic (colocalized with
KDEL); weak perinuclear
(–) Maric et al.89
Mouse fibroblast NIH-
3T3 cells
Diffuse cytoplasmic Perinuclear Jungwirth et al.90
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Table 1. Continued
Cell Type/Name WT-torsinA DE-torsinA References
Baby hamster kidney
fibroblast BHK21 cells
Diffuse cytoplasmic (colocalized with
KDEL); weak perinuclear (,20% of
cells); no inclusions (,0%)
Perinuclear (,70% of cells); with/
without inclusions (inclusions in









Diffuse cytoplasmic Perinuclear; with/without diffuse






Diffuse cytoplasmic (colocalized with
KDEL in 100% of cells); inclusions
(10% of cells); minimal perinuclear
(colocalized with laminB1 in 6% of
cells)
Inclusions (79% of cells; inclusions
were smaller than those in
overexpressed WT-torsinA);
colocalized with laminB1 in 89%;
colocalized with KDEL in 12%; not





Diffuse cytoplasmic (colocalized with
PDI); perinuclear (not colocalized with
PDI)
(–) Jungwirth et al.65
Baby hamster kidney
fibroblast BHK21 cells
Diffuse cytoplasmic Perinuclear Jungwirth et al.90
Chinese hamster ovary
epithelial-like CHO cells











Diffuse cytoplasmic (colocalized with
GRP78/BiP)
(–) Josse et al.94
Rat oligodendrocyte
OLN cells







Diffuse cytoplasmic (colocalized with
PDI)
Inclusions (colocalized with






Diffuse cytoplasmic Perinuclear; inclusions Hewett et al.40
Human neuroblastoma
SH-SY5Y cells
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Table 1. Continued
Cell Type/Name WT-torsinA DE-torsinA References
Human neuroblastoma
SH-SY5Y cells
Diffuse cytoplasmic (colocalized with
KDEL); perinuclear
Diffuse cytoplasmic (colocalized
with KDEL); more preferential












Perinuclear; inclusions Granata et al.38
Human neuroblastoma
SH-SY5Y cells
Diffuse cytoplasmic (colocalized with
PDI); no inclusions (found in ,4% of
cells)
Inclusions (found in ,100% of





Diffuse cytoplasmic; minimal inclusions
(,15% of cells); minimal perinuclear







Diffuse cytoplasmic (colocalized with
PDI)
Inclusions Hettich et al.77
Mouse neuroblastoma
N2A cells
Diffuse cytoplasmic (–) Armata et al.76
Mouse neural line CAD
cells (differentiated)
Punctate cytoplasmic in cell body and
neurite (colocalized with PDI, partially
with VAMP2); not perinuclear
Inclusions (colocalized with PDI,
but not with VAMP2 or GM130);
not perinuclear; TEM shows
torsinA and PDI in inclusions
Hewett et al.20
Mouse neural line CAD
cells
Diffuse cytoplasmic in cell body and
process
Inclusions (colocalized with KLC in
57% of cells)
Kamm et al.36
Mouse neural line CAD
cells
(–) Perinuclear; inclusions Naismith et al.18
Mouse neural line CAD
cells
Diffuse cytoplasmic; minimal inclusions
(,5% of cells)
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Table 1. Continued
Cell Type/Name WT-torsinA DE-torsinA References
Rat pheochromocytoma
PC6-3 cells
Diffuse cytoplasmic Perinuclear; inclusions Gordon and Gonzalez-
Alegre,23 Gordon et







Diffuse cytoplasmic in soma and
process; inclusions (,5% of all
neurons, ,0% of TH-negative
neurons, ,20% of TH-positive
neurons)
Inclusions (54% of all neurons, 43%
of TH-negative neurons, 84% of
TH-positive neurons) (colocalized
with TH, but not with PDI)
(TH-positive neurons comprised




Diffuse cytoplasmic in soma and
process
Perinuclear Nery et al.88
Rat dorsal root ganglion
neurons (3 DIV)
Diffuse cytoplasmic in soma; minimal
perinuclear (4% of neurons); no
inclusions (0% of neurons)

















inclusions; not perinuclear; ,twofold
increase in torsinA protein level in
comparison to non-transgenic control
mice
Same as in transgenic mice
overexpressing WT-torsinA or
non-transgenic control; ,twofold









(–) Inclusions (colocalized with lamin
A/C, ubiquitin); these changes
were absent in cerebral cortex,
hippocampus, striatum, substantia
nigra pars compacta, cerebellar
cortex
Shashidharan et al.100
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Table 1. Continued









Diffuse cytoplasmic in soma and
dendrite; inclusions (colocalized with
lamin A/C, ubiquitin-protein
conjugates, but not with PDI)
(inclusions not found in hippocampus,
striatum, substantia nigra, cerebellar
cortex); ,sixfold increase in human
protein level from non-transgenic
mice; high expression caused TEM
abnormality of nuclear envelope (30%




increase in human protein level
from non-transgenic mice; TEM
nuclear envelope abnormality
more frequent than in WT-
torsinA overexpression (,50% of








Diffuse cytoplasmic in soma and
proximal dendrite; no perinuclear; no
inclusions; human torsinA transcript
was not increased in comparison to
control human brains; no TEM
abnormality of nuclear envelope in




transgenic control; human torsinA
transcript was four-to-fivefold
higher than in control human
brains; no TEM abnormality of
nuclear envelope in striatum,
pontine nuclei, cerebellar cortex,
spinal cord
Zhao et al.27 (same
mice as reported in
Sharma et al.14)
Transgenic mouse,
neurons in olfactory bulb
Diffuse cytoplasmic in soma and
dendrite; inclusions in mitral cell; no
staining in dentate gyrus of
hippocampus or striatum







Diffuse/punctate cytoplasmic in soma
and proximal dendrite; no staining in
nucleoplasm, fibers
Diffuse/punctate cytoplasmic in
soma and proximal dendrite; no
staining in nucleoplasm or fibers.
Martella et al.102 (same










Diffuse cytoplasmic in soma and
proximal dendrite





(–) Same as in non-transgenic controls
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increase from the endogenous level).16 The fact that the expression
level is a strong determinant of at least the DE-torsinA distribution
pattern indicates that the localization would have to be extrapolated to
estimate the distribution of torsinA proteins at the low, endogenous
level. However, it is unclear how such extrapolation can be achieved
and, even if it is possible, to what extent the extrapolated properties
would reflect those of the endogenous proteins. As a side note, some
exceptions to the consistent overexpression results have been reported.
For example, DE-torsinA was mislocalized in the neuroblastoma cell
line SH-SY5Y but not in the non-neuronal HeLa cell line26 or in the
neurons of transgenic mice overexpressing human DE-torsinA14,27
(Table 1). This phenomenon can be explained if the expression levels
of wild-type and DE-torsinA were different in those studies.
Another disadvantage of the overexpression systems is their
dependence on the properties of the promoters used to express the
transgenes (promoters in transgenic animals have been reviewed in
Tassone et al.,28 Oleas et al.,29 and Richter and Richter30). For
instance, the commonly used human cytomegalovirus (CMV) major
immediate–early promoter/enhancer is considered strong, but its
effect is influenced by neuronal activity, with depolarization increasing
its efficiency more than 90-fold.31 Thus, expression will be low in
neurons with weak spontaneous activity, and such activity may be
masked by high expression in more active neurons. Moreover,
different promoters demonstrate different tissue specificities and
developmental expression profiles.32
In summary, the results obtained from overexpression systems are
mostly clear and consistent, albeit with a few exceptions. However,
caution is needed in interpreting them, especially with respect to the
subcellular localization of torsinA proteins, until such outcomes are
reliably replicated at endogenous levels of expression.
Inconsistent localization results for endogenous torsinA
Endogenous torsinA has been detected by indirect immunocyto-
chemistry. The primary anti-torsinA antibody is detected using a
secondary antibody conjugated with a fluorescent probe (fluorophore)
or an enzyme that synthesizes colored or electron-dense product.33 For
a partial list of torsinA antibodies, see Xiao et al.34 In sharp contrast to
the outcomes for overexpression systems, the reported distribution of
the endogenous torsinA protein is fairly inconsistent (Table 3).
In the case of in vitro studies, the cytoplasmic distribution of wild-type
torsinA was typically diffuse, but it was punctate in a pattern consistent
with vesicle staining in immature neurons and neuron-like tumor
Table 1. Continued
Cell Type/Name WT-torsinA DE-torsinA References
Transgenic rat, neurons
in olfactory bulb, cerebral
cortex, hippocampus,
striatum, substantia nigra
Diffuse cytoplasmic in soma and
proximal dendrite (not colocalized
with lamin A/C that showed
continuous curve); normal TEM of
nuclear envelope; protein expression
level was not specified for
morphological studies
Perinuclear in a discontinuous
pattern (colocalized with lamin
A/C); abnormal TEM of nuclear
envelope; not expressed in pons,
cerebellum, brainstem; torsinA
protein expression level was
,sevenfold higher than the lowest
expressing line
Grundmann et al.103
In this article, ‘‘perinuclear’’ indicates ring-like staining of the nuclear envelope completely surrounding the nucleoplasm. ‘‘Inclusions’’ indicate intracellular, cytoplasmic
inclusion bodies, except where intranuclear inclusion is specifically mentioned in Table 3. The cytoplasmic inclusions were often located near cellular nuclei. (–)
indicates not tested.
Table 1 includes results with human torsinA, except for one study that analyzed porcine torsinA (mentioned as such).
Table 1 and Table 2 include both controlled and uncontrolled expression of the exogenous transgene.
In Tables 1–3, the results are limited to the distributions of wild-type and DE-torsinA. They do not include other naturally occurring mutations or genetically
engineered proteins. Results from experimental manipulations that could affect the torsinA distribution were not included. Such manipulations are, e.g., the co-
transfection with non-torsinA transgene constructs, the induction of cellular stress and ischemic insults, and the pharmacological regulation of biological processes.
Abbreviations and comments in Tables 1–3: calbindin D-28K (Purkinje neuron marker); calnexin (ER marker); ChAT, Choline Acetyltransferase (cholinergic neuron
marker); CSN4, COP9 signalosome complex subunit 4; DIV, Days In Vitro; EM, Electron Microscopy; emerin (nuclear envelope marker); ER, Endoplasmic Reticulum;
GABA, c-Aminobutyric Acid (inhibitory neurotransmitter); GFAP, Glial Fibrillary Acidic Protein (astrocyte marker); GM130, Golgi Matrix protein of 130 kDa (Golgi
apparatus marker); GRP78/BiP, Glucose-Regulated Protein of 78 kDa/Binding Immunoglobulin Protein, also known as heat shock 70 kDa protein 5 (HSPA5) (ER
marker); KDEL, Lysine-Aspartic Acid-Glutamic Acid-Leucine Sequence (ER retention signal); KLC, Kinesin Light Chain (motor protein); lamins (nuclear envelope
markers); NOS, Nitric Oxide Synthase (marker of a class of GABAergic neurons); NSE, Neuron-Specific Enolase (neuronal marker); nucleoporin (nuclear envelope
marker); parvalbumin (marker of a class of GABAergic neurons); PDI, Protein Disulfide Isomerase (ER marker); SGI, Secretogranin I (secretory granule marker); snapin
(SNAP25 [synaptosomal associated protein of 25 kDa]-binding protein); somatostatin (marker of a class of GABAergic neurons); TEM, Transmission Electron
Microscopy; TH, Tyrosine Hydroxylase (dopaminergic/noradrenergic neuron marker); VAMP2, Vesicle-Associated Membrane Protein/Synaptobrevin 2 (synaptic
vesicle/nerve terminal marker); VGAT, Vesicular GABA Transporter (GABAergic nerve terminal marker); VGLUT1 and 2, Vesicular Glutamate Transporters 1 and 2
(glutamatergic nerve terminal markers); VMAT2, Vesicular Monoamine Transporter 2 (monoaminergic marker); WT, wild type; DE, deletion of a single GAG codon in
TOR1A or Tor1a gene (associated with DYT1 dystonia).
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cells.35–38 In addition, wild-type torsinA was present in neurites and
growth cones of immature cells,35–38 whereas it was not detectable in
axonal shafts or nerve terminals of more mature neurons.39 In the
fibroblasts of DYT1 dystonia patients, perinuclear staining was
reported in one study10 but was absent in others.40,41 Notably,
staining of cytoplasmic inclusions was absent in all cases, consistent
with findings from studies in fibroblasts from control subjects.10,40,41
In the case of neurons in situ, the results were more variable than
those described above. The majority of studies found that wild-type
torsinA was distributed diffusely throughout the cytoplasm of the
somata and proximal dendrites. However, the following patterns were
also described: strong staining of axons and nerve terminals;42–45
strong staining of the neuropil without staining of somata or
dendrites;46 staining of the proximal dendrites of some but not all
neurons;47 and staining of the nucleoplasm.47,48 Of interest is the
notion that the torsinA-positive domain of the neuron does not
completely overlap with the ER.49 Even after nucleoplasmic staining
was excluded, the torsinA staining covered only a portion of the
cytoplasm,47,48 suggesting that a non-ER compartment could be
stained. In the brains of DYT1 dystonia patients, the distribution of
torsinA protein was the same as in those from control subjects, i.e., a
lack of staining of inclusions or the nuclear envelope,44,49 although
cytoplasmic inclusions were found in brainstem regions.50
Approaches to filling the gap
The discrepancies in the distribution results for exogenous and
endogenous torsinA proteins mainly arise from variation in the
reported distribution of endogenous torsinA. It is difficult to interpret
the results of overexpression studies, given that the pattern or
determinant of endogenous localization is not yet clear. The latter
could reflect genuine variations in the biology of this protein, reflecting
subtle differences and changes in torsinA expression. It is also possible
that the subcellular distribution of torsinA differs by cell type, by brain
region, by species, and/or developmental stage, and there may even be
intrinsic variation among individuals. Furthermore, in the case of
human brains, the levels of protein expression may be affected by how,
and for how long, the subjects had experienced pathological stresses
before death, because torsinA expression at both the mRNA51 and
protein52 levels is regulated by insults.
Before discussing these interesting variations of biological impor-
tance, however, it should be stated that the more likely causes of
variation are technical issues concerning specificity and efficiency in
detecting endogenous torsinA. Identifying the sources of any technical
complications will help explain the discrepancies in the observed
distributions for exogenous and endogenous torsinA.
One potentially important challenge in comparing the data for the
two types of expression is that the lower level of expression for
endogenous torsinA will make it difficult to distinguish positive signals
from background noise. Importantly, any factor that negatively
influences the immunocytochemical detection procedures may affect
interpretation. Thus, it will be particularly important to test whether
each step in the immunocytochemical procedure is working properly
and is optimized, in both in vitro and in situ studies, and at both the light
and the electron microscopy levels. The following are ways that future
Table 2. Subcellular Distributions of Human TorsinA Proteins at Different Overexpression Levels
Cell type/name WT-torsinA DE-torsinA References
Human glioma Gli36 cells







Perinuclear when expression level is
low to moderate (two- to 10-fold
increase from endogenous level);
additional inclusions when the level is











Perinuclear when expression level is
low to moderate; additional inclusions






(–) Perinuclear when the expression level
is low; additional, diffuse cytoplasmic






(–) Perinuclear and diffuse cytoplasmic
when expression level is low;
additional inclusions when the level is
high (e.g. fourfold higher than the low
expression)
Naismith et al.18
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Table 3. Subcellular Localization of Endogenous TorsinA Proteins in Mammalian Systems
Cell type/name WT-torsinA DE-torsinA References
Cultured non-neuronal
cells















Mouse embryonic fibroblasts Diffuse cytoplasmic (partially colocalized
with KDEL)





Diffuse cytoplasmic in cell body;
nucleoplasm
(–) Hewett et al.66
Human neuroblastoma SH-
SY5Y cells (differentiated)
Punctate cytoplasmic in cell body;
punctate accumulation in neurite





Diffuse cytoplasmic in cell body
(colocalized with KDEL) (processes were
not present)
(–) Giles et al.95
Human neuroblastoma SH-
SY5Y cells
Punctate cytoplasmic in cell body and
process (colocalized with CSN4)
(–) Granata et al.38
Human neuroglioma H4 cells Diffuse cytoplasmic in cell body; no
inclusions
(–) McLean et al.104
Rat pheochromocytoma
PC12 cells (differentiated)
Diffuse cytoplasmic in cell body and
process (colocalized with PDI)
(–) Hewett et al.72
Rat pheochromocytoma
PC12 cells (differentiated)
Punctate accumulation in neurite tip
(colocalized with snapin, SGI)








Diffuse cytoplasmic (colocalized with
KDEL); some perinuclear (more localized
to nuclear envelope than in embryonic
fibroblasts in the same study)
(–) Giles et al.26
Mouse cerebral cortical
neurons
Diffuse cytoplasmic (–) Kim et al.105
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Table 3. Continued
Cell type/name WT-torsinA DE-torsinA References
Mouse hippocampal neurons
(4 DIV)
Punctate cytoplasmic in soma and
process (colocalized with snapin)
(–) Granata et al.37
Mouse cerebellar granule
neurons (4–6 DIV)
Punctate cytoplasmic in soma and neurite
(colocalized with CSN4)






Proximal dendrite; absent from axon and
nerve terminal; soma was not evaluated
Same as in WT-torsinA;
(Tor1a+/DE and Tor1aDE/DE)
Koh et al.39
Rat cerebral cortical neurons
(8 DIV)
Punctate cytoplasmic in soma, neurite,
growth cone (colocalized with KLC1)
(–) Kamm et al.36
Neurons in situ




Diffuse cytoplasmic in soma, proximal
dendrite; nucleoplasm; no staining of
white matter
(–) Shashidharan et al.48
Human neurons in cerebral
cortex, substantia nigra pars
compacta (in Parkinson’s
disease)
Positive staining in intracellular Lewy
bodies (that are positive for a-synuclein)
(–) Shashidharan et al.69







Diffuse/punctate cytoplasmic in soma,
proximal dendrite; fibers in white matter,
brachium of superior colliculus, etc; no
staining of nucleoplasm
(–) Konakova et al.42
Human neurons in
hippocampus, substantia nigra
(in diffuse Lewy body disease)
No staining of soma or dendrite; positive
staining in Lewy bodies (colocalized with
a-synuclein and ubiquitin, but closely
associated with only a-synuclein at
,30-nm resolution).
(–) Sharma et al.106
Human neurons in substantia
nigra (in dementia with Lewy
body disease)
No staining of soma or dendrite; positive
staining in Lewy bodies (colocalized with
a-synuclein which in turn is colocalized
with heat shock proteins)
(–) McLean et al.104






Punctate cytoplasmic in soma (limited
colocalization with PDI); proximal
dendrite; nucleoplasm (sparing nucleoli);
punctate neuropil (putative nerve
terminals); no inclusions; not perinuclear
Same as in WT-torsinA;
patient’s brain (TOR1A+/DE)
Walker et al.49
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Table 3. Continued
Cell type/name WT-torsinA DE-torsinA References




spinocerebellar ataxia type III,
and Huntington’s disease-like
2 which had previously been
diagnosed as chorea-
acanthocytosis107)
Positive in intranuclear inclusion bodies
(that are positive for ubiquitin, expanded
polyglutamine repeats)
(–) Walker et al.108,109
Human neurons in
hippocampus, caudate-




Punctate cytoplasmic in soma, proximal
dendrite; some axons and ‘‘pencil bundle
fibers’’ (axons of medium spiny neurons
in caudate-putamen); punctate neuropil
(putative nerve terminals)
Same as in WT-torsinA; no
inclusions; only caudate-
putamen and substantia nigra
pars compacta were analyzed






No staining of soma or dendrite;
punctate neuropil (putative axon, nerve
terminals; vesicles in axons (immuno-
EM).





No inclusions Inclusions (colocalized with
laminA/C, ubiquitin-protein
conjugates, ubiquitin, but
weakly with PDI); these







Human neurons in substantia
nigra (in diffuse Lewy body
disease)







cortex, dentate nucleus of
deep cerebellar nuclei, during
development
Diffuse/punctate cytoplasmic in soma,
proximal dendrite; putative axon and
nerve terminal; no nucleoplasm; no
staining before postnatal 6 weeks
(–) Siegert et al.70
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Table 3. Continued





normal subjects and patients
with non-DYT1 dystonia)
No inclusions (–) Holton et al.110
Patus monkey neurons in
hippocampus
Nucleoplasm, axon, nerve terminal
(immuno-EM); no other compartments
were analyzed
(–) Walker et al.43
Macaque monkey neurons in
putamen
No staining of soma or dendrite; staining
in neuropil; vesicles in nerve terminals
(immuno-EM).
(–) Augood et al.46




compacta, motor nucleus of
trigeminal nerve, cerebellar
cortex
Strong staining of fibers in cerebral
cortical white matter, corpus callosum,
internal capsule, anterior commissure,
cerebral peduncle, etc; diffuse/punctate
cytoplasmic in soma, proximal dendrite
(–) Konakova and Pulst45




Diffuse cytoplasmic in soma (colocalized
with PDI, but not with lamin A/C or
ubiquitin)
(–) Shashidharan et al.100
Mouse neurons in cerebral
cortex, substantia nigra pars
compacta, pontine nuclei of
DE-torsinA knock-in model
Diffuse cytoplasmic in soma; no
inclusions in brains of male or female
mice
Inclusions only in pontine
nuclei of male mice
(colocalized with ubiquitin)
(not found in female mice)
(Tor1a+/DE)
Dang et al.111
Mouse neurons in striatum
(cholinergic interneurons)
Diffuse cytoplasmic in soma and proximal
dendrite
(–) Sciamanna et al.75
Mouse neurons in cerebellar
cortex, deep cerebellar nuclei
Diffuse/punctate cytoplasmic in soma,
dendrite, dendritic spine (partially
colocalized with calbindin D-28K,
parvalbumin), nerve terminal (partially
colocalized with VGLUT1, VGLUT2,
VGAT); nucleoplasm of neurons
expressing high level of torsinA
(–) Puglisi et al.71
Mouse neurons in red





Diffuse cytoplasmic (expression level was
,60% of Tor1a+/DE mice) (nestin-Cre
control mouse)
Perinuclear (expression level
was ,20% of Tor1a+/DE mice)
(Tor1a2/DE)
Liang et al.61
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studies can achieve such optimization, as suggested for immunocyto-
chemical reports more generally.33,53–55
Firstly, it will be important to test primary antibodies for their
specificity in binding to the antigen. The literature suggests at least five
controls for general immunocytochemical procedures.53–55 The first
control is to manipulate expression of the antigen. Suggested
approaches are genetic deletion in knock-out animals or down-
regulation by RNA interference. A variation of this test is to upregulate
the antigen, for example, by overexpressing GFP-tagged antigen, and
detecting this protein simultaneously by GFP fluorescence and
immunocytochemistry using secondary antibody conjugated with a
different fluorophore.55 A drawback of this approach is that
predominance of the overexpressed antigen can mask the specificity
of a weak antibody. The second control is to preadsorb the antibody
with the immunizing peptide. The third control is to compare the
specificity of immunostaining at the cellular level to mRNA expression
as assessed by in situ hybridization, taking into consideration that the
two signals may be detected in different subcellular compartments.
The fourth control is to test the antibody for overlap of its signal with
that from other antibodies raised against non-overlapping epitopes of
the same protein. The feasibility of this approach depends on the
repertoire of available antibodies. The fifth control is to test the ability
of the antibody to detect a single protein entity by Western blotting.
However, in this case it needs to be born in mind that the proteins are
Table 3. Continued
Cell type/name WT-torsinA DE-torsinA References




Nucleoplasm; diffuse cytoplasmic in
soma, proximal dendrite (partially
colocalized with TH)
(–) Shashidharan et al.48
Rat neurons in cerebral
cortex, hippocampus,
striatum, cerebellar cortex
Nucleoplasm (sparing nucleoli); diffuse
cytoplasmic in soma (partially colocalized
with NSE, NOS, parvalbumin, GABA or
ChAT), proximal dendrites of some but
not all neurons; punctate neuropil
(putative nerve terminals)
(–) Walker et al.47
Rat neurons in cerebral
cortex, hippocampus,
striatum, substantia nigra pars
compacta, cerebellar cortex
Diffuse cytoplasmic in soma, dendrite;
not perinuclear or nucleoplasmic;
punctate ‘‘pencil fiber bundle’’ axons in
young striatum
(–) Xiao et al.34




Cytoplasm in soma, processes; increased
staining intensity during postnatal 7 to 28
days
(–) Oberlin et al.112
Rat neurons in striatum,
globus pallidus, subthalamic
nucleus
Nucleoplasm (sparing nucleoli); less
strong in perikaryal cytoplasm and
proximal dendrite
(–) Yamada et al.113
Rat neurons in hippocampus Diffuse cytoplasmic in soma, proximal
dendrite of pyramidal neurons and
parvalbumin- or somatostatin-positive
interneurons
(–) Zhao et al.52
Rat neurons in dorsal root
ganglion
Diffuse cytoplasmic in soma; axon (–) Zhao et al.52
Note that the cells of DYT1 dystonia patients are listed under ‘‘DE-torsinA.’’ However, they are heterozygous for the mutant allele (TOR1A+/DE), i.e., both wild-type and
DE-torsinA proteins will be present. Similarly, heterozygous DE-torsinA knock-in mice (Tor1a+/DE) will express two types of full-length proteins. In contrast, the
homozygous DE-torsinA knock-in mice (Tor1aDE/DE) express only the DE-torsinA protein, and the brain-restricted nestin-Cre Tor1aflox/DE mice express the DE-torsinA
protein and exons 1 and 2 (out of exons 1–5) of wild-type protein (i.e., effectively Tor1a2/DE).
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in different states with respect to their secondary, tertiary and
quaternary structures when recognized by immunocytochemistry vs.
Western blotting (denatured by sodium dodecyl sulfate, heat or
reducing condition), and thus this test could produce irrelevant
information. Controls of these types are especially important for
polyclonal antibodies, given that they identify multiple epitopes in the
antigen (torsinA), some of which could be shared with non-related
proteins. Such non-specific binding is less likely to occur with
monoclonal antibodies, for which the epitopes are specific peptide
sequences that are not shared with other proteins.
Secondly, it will likewise be vital to control secondary antibodies for
their specificity in binding to a primary antibody of interest. A typical
method is to omit the primary antibody, and examine whether the
signal is eliminated.53,55 Omission of both the primary and secondary
antibodies will establish to what extent the native tissue produces
background noise, e.g., autofluorescence (‘‘label control’’ in Burry55).
Thirdly, other aspects of immunocytochemical procedures will also
require careful optimization. These include: the concentration of the
primary antibody (e.g., too high a concentration leads to non-specific
staining33); the type and duration of chemical fixation (e.g., one
torsinA antibody was incompatible with procedures of cryo-immuno-
electron microscopy37); and the type of embedding medium (e.g.,
paraffin embedding under heat can reduce the antigenicity). These
aspects are especially important for in situ studies, because the
procedures typically take longer than those required for in vitro studies
and are therefore more susceptible to artifacts caused by non-ideal
conditions. For example, animal tissues are chemically fixed for a
prolonged period of time, first by trans-cardiac perfusion with a
fixative (perfusion fixation) for ,30 min, and second by immersion of
the tissue in the same fixative (immersion post-fixation) for one to two
days. In contrast, cultured cells are typically fixed (immersion fixation)
for ,30 min only. If torsinA antigenicity is affected by the duration of
fixation, the results can be variable depending on the protocols used in
individual experiments.
Lastly, not only the staining of samples, but also the imaging of
signals can be affected by numerous factors. The first is optical
resolution along the focal axis (in the z-direction). Resolution is limited
to ,1 mm even when optical sectioning is carried out by confocal
microscopy, and it is worse in the case of widefield microscopy.56
Therefore, when paraffin sections (e.g., 3-mm thickness57,58) and
floating sections (e.g., 50-mm thickness59) are used, the signal detected
at any focal plane will be affected by stray signal from adjacent
structures in other focal planes. Some forms of super-resolution
fluorescence imaging will suffer from the same problem in thick
sections. This issue is best resolved when ultrathin sectioning is
achieved physically (e.g., 50–200 nm).60 Second, the level of the focal
plane is important because of the poor z-resolution of light microscopy.
Even a non-diffuse signal can look diffuse and be mistaken as ER-like if
the focal plane is outside the target structure. Third, it is essential to
keep the imaging parameters at the same values (e.g., intensity setting
and exposure time).55 Otherwise, increasing the detection sensitivity
could inappropriately lead to the inclusion of background noise as
positive signal, and to an incorrect interpretation such as a diffuse ER-
like pattern.
The influences of the technical aspects discussed above have not
been extensively evaluated in the field of DYT1 dystonia, although
considerable efforts have been made. These include using the torsinA
knock-out tissue in immunostaining61 or Western blotting,61,62 using
antisense knock-down in immunostaining35,63,64 or Western blot-
ting,35,38,63,65 Western blotting using torsinA-overexpressing
cells,15,17,20,21,23,40,46,48,66–68 antigen preadsorption test in cellular
staining39,42,44,45,47,48,69–71 or Western blotting,20,42,45,72 secondary
antibody controls,34,36,39,44,47,49,50,71 and the spatial range of signal
spread in tissue.71
The key to definitive resolution of torsinA localization will be to
evaluate these parameters for each antibody using each protocol, and
using each tissue of interest in a given species. We understand that
these efforts will be labor-intensive, and also that it will not be feasible
to use such controls in studying human brains. However, systematic
evaluation in at least the cellular and animal models will produce
reliable immunocytochemical data that can be compared qualitatively
to that produced in overexpression studies.
Of note, although species-specific antibodies are available,23,73 one
of the current challenges is that no antibody available can distinguish
between the wild-type and DE-torsinA proteins.11,13,39,74,75 The study
of torsinA distribution will be significantly improved if antibodies or
other tools capable of doing so are developed.
Conclusions
Knowledge of the subcellular distribution of torsinA will be critical
for understanding how wild-type torsinA affects neuronal function, as
well as how DE-torsinA leads to neuronal dysfunction. This
information will help researchers narrow down the potential
pathophysiological roles of torsinA in DYT1 dystonia. For this
purpose, it will be important to reassess the prevailing model of
torsinA distribution based on exogenous torsinA, after the endogenous
distribution is reliably established. Such reassessments will be valuable
regardless of the precise outcome. Should the endogenous and
exogenous distributions match, torsinA mislocalization in the model
will be reinforced as one of the key events in pathogenesis. Should they
differ, it will indicate that DE-torsinA is mislocalized as a consequence
of abnormally high expression. In this case the new results will be
particularly important in providing novel insights into pathophysiolo-
gical mechanisms. Even under such conditions, it should be
emphasized that this article is not aimed at downplaying the value of
overexpression studies. Such studies make it possible, for example, to
modify the molecular structure of torsinA and to identify regulatory
interacting partners. Nevertheless, at this point, it will be essential to
establish whether overexpression studies truly reflect the roles of
endogenous torsinA and the pathogenesis of DYT1 dystonia.
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